Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak

Attributes contributing to the current monkeypox virus (MPXV) outbreak remain unknown. It has been established that mutations in viral proteins may alter phenotype and pathogenicity. To assess if mutations in the MPXV DNA replication complex (RC) contribute to the outbreak, we conducted a temporal a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of autoimmunity 2022-12, Vol.133, p.102928-102928, Article 102928
Hauptverfasser: Kannan, Saathvik R., Sachdev, Shrikesh, Reddy, Athreya S., Kandasamy, Shree Lekha, Byrareddy, Siddappa N., Lorson, Christian L., Singh, Kamal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 102928
container_issue
container_start_page 102928
container_title Journal of autoimmunity
container_volume 133
creator Kannan, Saathvik R.
Sachdev, Shrikesh
Reddy, Athreya S.
Kandasamy, Shree Lekha
Byrareddy, Siddappa N.
Lorson, Christian L.
Singh, Kamal
description Attributes contributing to the current monkeypox virus (MPXV) outbreak remain unknown. It has been established that mutations in viral proteins may alter phenotype and pathogenicity. To assess if mutations in the MPXV DNA replication complex (RC) contribute to the outbreak, we conducted a temporal analysis of available MPXV sequences to identify mutations, generated a DNA replication complex (RC) using structures of related viral and eukaryotic proteins, and structure prediction method AlphaFold. Ten mutations within the RC were identified and mapped onto the RC to infer role of mutations. Two mutations in F8L (RC catalytic subunit), and two in G9R (a processivity factor) were ∼100% prevalent in the 2022 sequences. F8L mutation L108F emerged in 2022, whereas W411L emerged in 2018, and persisted in 2022. L108 is topologically located to enhance DNA binding affinity of F8L. Therefore, mutation L108F can change the fidelity, sensitivity to nucleoside inhibitors, and processivity of F8L. Surface exposed W411L likely affects the binding of regulatory factor(s). G9R mutations S30L and D88 N in G9R emerged in 2022, and may impact the interaction of G9R with E4R (uracil DNA glycosylase). The remaining six mutations that appeared in 2001, reverted to the first (1965 Rotterdam) isolate. Two nucleoside inhibitors brincidofovir and cidofovir have been approved for MPXV treatment. Cidofovir resistance in vaccinia virus is achieved by A314T and A684V mutations. Both A314 and A684 are conserved in MPXV. Therefore, resistance to these drugs in MPXV may arise through similar mechanisms. •L108F in MPXV DNA polymerase emerged in the 2022 outbreak.•L108F can enhance DNA binding affinity, processivity and drug sensitivity of F8L.•Mutation L108F can change the fidelity and sensitivity to nucleoside inhibitors.•G9R mutations that emerged in 2022, are likely to affect interaction of G9R with E4R.
doi_str_mv 10.1016/j.jaut.2022.102928
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9562781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0896841122001366</els_id><sourcerecordid>2725651883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-571f141b664d1dffc545277a6acfe6ed1ebde516fb789750a00a8df6743b13713</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhC3BAPnLJ4nFiO0EIqar4JxW1BzhbjjNpvU3sYDur9tuTdEvVXjiNNPObN0_zCHkLbAsM5IfddmfmvOWM86XBG14_IxtgjSgaEOo52bC6kUVdARyRVyntGAMQQrwkR6Xkglei2RD3c84mu-ATdZ7mK6Rj8Nd4O4UbundxTjTiNDh7x1AbxmnAm4_0ImT02ZlhafkcXTtn5y9pb2wOMdEc7qRWZzTMuY1orl-TF70ZEr65r8fk99cvv06_F2fn336cnpwVthIiF0JBDxW0UlYddH1vRSW4UkYa26PEDrDtUIDsW1U3SjDDmKm7XqqqbKFUUB6TzwfdaW5H7OziM5pBT9GNJt7qYJx-OvHuSl-GvW6E5KpeBd7fC8TwZ8aU9eiSxWEwHsOcNFdcSAF1XS4oP6A2hpQi9g9ngOk1I73Ta0Z6_YQ-ZLQsvXts8GHlXygL8OkA4PKmvcOok3XoLXYuos26C-5_-n8BZ1alrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2725651883</pqid></control><display><type>article</type><title>Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kannan, Saathvik R. ; Sachdev, Shrikesh ; Reddy, Athreya S. ; Kandasamy, Shree Lekha ; Byrareddy, Siddappa N. ; Lorson, Christian L. ; Singh, Kamal</creator><creatorcontrib>Kannan, Saathvik R. ; Sachdev, Shrikesh ; Reddy, Athreya S. ; Kandasamy, Shree Lekha ; Byrareddy, Siddappa N. ; Lorson, Christian L. ; Singh, Kamal</creatorcontrib><description>Attributes contributing to the current monkeypox virus (MPXV) outbreak remain unknown. It has been established that mutations in viral proteins may alter phenotype and pathogenicity. To assess if mutations in the MPXV DNA replication complex (RC) contribute to the outbreak, we conducted a temporal analysis of available MPXV sequences to identify mutations, generated a DNA replication complex (RC) using structures of related viral and eukaryotic proteins, and structure prediction method AlphaFold. Ten mutations within the RC were identified and mapped onto the RC to infer role of mutations. Two mutations in F8L (RC catalytic subunit), and two in G9R (a processivity factor) were ∼100% prevalent in the 2022 sequences. F8L mutation L108F emerged in 2022, whereas W411L emerged in 2018, and persisted in 2022. L108 is topologically located to enhance DNA binding affinity of F8L. Therefore, mutation L108F can change the fidelity, sensitivity to nucleoside inhibitors, and processivity of F8L. Surface exposed W411L likely affects the binding of regulatory factor(s). G9R mutations S30L and D88 N in G9R emerged in 2022, and may impact the interaction of G9R with E4R (uracil DNA glycosylase). The remaining six mutations that appeared in 2001, reverted to the first (1965 Rotterdam) isolate. Two nucleoside inhibitors brincidofovir and cidofovir have been approved for MPXV treatment. Cidofovir resistance in vaccinia virus is achieved by A314T and A684V mutations. Both A314 and A684 are conserved in MPXV. Therefore, resistance to these drugs in MPXV may arise through similar mechanisms. •L108F in MPXV DNA polymerase emerged in the 2022 outbreak.•L108F can enhance DNA binding affinity, processivity and drug sensitivity of F8L.•Mutation L108F can change the fidelity and sensitivity to nucleoside inhibitors.•G9R mutations that emerged in 2022, are likely to affect interaction of G9R with E4R.</description><identifier>ISSN: 0896-8411</identifier><identifier>ISSN: 1095-9157</identifier><identifier>EISSN: 1095-9157</identifier><identifier>DOI: 10.1016/j.jaut.2022.102928</identifier><identifier>PMID: 36252459</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>DNA replication complex ; F8L ; Family B polymerase ; G9R ; Monkeypox virus ; Mpox (monkeypox) ; Mutation ; Mutations ; Nucleosides ; Virus Replication - genetics</subject><ispartof>Journal of autoimmunity, 2022-12, Vol.133, p.102928-102928, Article 102928</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Ltd.</rights><rights>2022 Published by Elsevier Ltd. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-571f141b664d1dffc545277a6acfe6ed1ebde516fb789750a00a8df6743b13713</citedby><cites>FETCH-LOGICAL-c455t-571f141b664d1dffc545277a6acfe6ed1ebde516fb789750a00a8df6743b13713</cites><orcidid>0000-0001-6153-8929</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0896841122001366$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36252459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kannan, Saathvik R.</creatorcontrib><creatorcontrib>Sachdev, Shrikesh</creatorcontrib><creatorcontrib>Reddy, Athreya S.</creatorcontrib><creatorcontrib>Kandasamy, Shree Lekha</creatorcontrib><creatorcontrib>Byrareddy, Siddappa N.</creatorcontrib><creatorcontrib>Lorson, Christian L.</creatorcontrib><creatorcontrib>Singh, Kamal</creatorcontrib><title>Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak</title><title>Journal of autoimmunity</title><addtitle>J Autoimmun</addtitle><description>Attributes contributing to the current monkeypox virus (MPXV) outbreak remain unknown. It has been established that mutations in viral proteins may alter phenotype and pathogenicity. To assess if mutations in the MPXV DNA replication complex (RC) contribute to the outbreak, we conducted a temporal analysis of available MPXV sequences to identify mutations, generated a DNA replication complex (RC) using structures of related viral and eukaryotic proteins, and structure prediction method AlphaFold. Ten mutations within the RC were identified and mapped onto the RC to infer role of mutations. Two mutations in F8L (RC catalytic subunit), and two in G9R (a processivity factor) were ∼100% prevalent in the 2022 sequences. F8L mutation L108F emerged in 2022, whereas W411L emerged in 2018, and persisted in 2022. L108 is topologically located to enhance DNA binding affinity of F8L. Therefore, mutation L108F can change the fidelity, sensitivity to nucleoside inhibitors, and processivity of F8L. Surface exposed W411L likely affects the binding of regulatory factor(s). G9R mutations S30L and D88 N in G9R emerged in 2022, and may impact the interaction of G9R with E4R (uracil DNA glycosylase). The remaining six mutations that appeared in 2001, reverted to the first (1965 Rotterdam) isolate. Two nucleoside inhibitors brincidofovir and cidofovir have been approved for MPXV treatment. Cidofovir resistance in vaccinia virus is achieved by A314T and A684V mutations. Both A314 and A684 are conserved in MPXV. Therefore, resistance to these drugs in MPXV may arise through similar mechanisms. •L108F in MPXV DNA polymerase emerged in the 2022 outbreak.•L108F can enhance DNA binding affinity, processivity and drug sensitivity of F8L.•Mutation L108F can change the fidelity and sensitivity to nucleoside inhibitors.•G9R mutations that emerged in 2022, are likely to affect interaction of G9R with E4R.</description><subject>DNA replication complex</subject><subject>F8L</subject><subject>Family B polymerase</subject><subject>G9R</subject><subject>Monkeypox virus</subject><subject>Mpox (monkeypox)</subject><subject>Mutation</subject><subject>Mutations</subject><subject>Nucleosides</subject><subject>Virus Replication - genetics</subject><issn>0896-8411</issn><issn>1095-9157</issn><issn>1095-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhC3BAPnLJ4nFiO0EIqar4JxW1BzhbjjNpvU3sYDur9tuTdEvVXjiNNPObN0_zCHkLbAsM5IfddmfmvOWM86XBG14_IxtgjSgaEOo52bC6kUVdARyRVyntGAMQQrwkR6Xkglei2RD3c84mu-ATdZ7mK6Rj8Nd4O4UbundxTjTiNDh7x1AbxmnAm4_0ImT02ZlhafkcXTtn5y9pb2wOMdEc7qRWZzTMuY1orl-TF70ZEr65r8fk99cvv06_F2fn336cnpwVthIiF0JBDxW0UlYddH1vRSW4UkYa26PEDrDtUIDsW1U3SjDDmKm7XqqqbKFUUB6TzwfdaW5H7OziM5pBT9GNJt7qYJx-OvHuSl-GvW6E5KpeBd7fC8TwZ8aU9eiSxWEwHsOcNFdcSAF1XS4oP6A2hpQi9g9ngOk1I73Ta0Z6_YQ-ZLQsvXts8GHlXygL8OkA4PKmvcOok3XoLXYuos26C-5_-n8BZ1alrw</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Kannan, Saathvik R.</creator><creator>Sachdev, Shrikesh</creator><creator>Reddy, Athreya S.</creator><creator>Kandasamy, Shree Lekha</creator><creator>Byrareddy, Siddappa N.</creator><creator>Lorson, Christian L.</creator><creator>Singh, Kamal</creator><general>Elsevier Ltd</general><general>Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6153-8929</orcidid></search><sort><creationdate>20221201</creationdate><title>Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak</title><author>Kannan, Saathvik R. ; Sachdev, Shrikesh ; Reddy, Athreya S. ; Kandasamy, Shree Lekha ; Byrareddy, Siddappa N. ; Lorson, Christian L. ; Singh, Kamal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-571f141b664d1dffc545277a6acfe6ed1ebde516fb789750a00a8df6743b13713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>DNA replication complex</topic><topic>F8L</topic><topic>Family B polymerase</topic><topic>G9R</topic><topic>Monkeypox virus</topic><topic>Mpox (monkeypox)</topic><topic>Mutation</topic><topic>Mutations</topic><topic>Nucleosides</topic><topic>Virus Replication - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kannan, Saathvik R.</creatorcontrib><creatorcontrib>Sachdev, Shrikesh</creatorcontrib><creatorcontrib>Reddy, Athreya S.</creatorcontrib><creatorcontrib>Kandasamy, Shree Lekha</creatorcontrib><creatorcontrib>Byrareddy, Siddappa N.</creatorcontrib><creatorcontrib>Lorson, Christian L.</creatorcontrib><creatorcontrib>Singh, Kamal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of autoimmunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kannan, Saathvik R.</au><au>Sachdev, Shrikesh</au><au>Reddy, Athreya S.</au><au>Kandasamy, Shree Lekha</au><au>Byrareddy, Siddappa N.</au><au>Lorson, Christian L.</au><au>Singh, Kamal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak</atitle><jtitle>Journal of autoimmunity</jtitle><addtitle>J Autoimmun</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>133</volume><spage>102928</spage><epage>102928</epage><pages>102928-102928</pages><artnum>102928</artnum><issn>0896-8411</issn><issn>1095-9157</issn><eissn>1095-9157</eissn><abstract>Attributes contributing to the current monkeypox virus (MPXV) outbreak remain unknown. It has been established that mutations in viral proteins may alter phenotype and pathogenicity. To assess if mutations in the MPXV DNA replication complex (RC) contribute to the outbreak, we conducted a temporal analysis of available MPXV sequences to identify mutations, generated a DNA replication complex (RC) using structures of related viral and eukaryotic proteins, and structure prediction method AlphaFold. Ten mutations within the RC were identified and mapped onto the RC to infer role of mutations. Two mutations in F8L (RC catalytic subunit), and two in G9R (a processivity factor) were ∼100% prevalent in the 2022 sequences. F8L mutation L108F emerged in 2022, whereas W411L emerged in 2018, and persisted in 2022. L108 is topologically located to enhance DNA binding affinity of F8L. Therefore, mutation L108F can change the fidelity, sensitivity to nucleoside inhibitors, and processivity of F8L. Surface exposed W411L likely affects the binding of regulatory factor(s). G9R mutations S30L and D88 N in G9R emerged in 2022, and may impact the interaction of G9R with E4R (uracil DNA glycosylase). The remaining six mutations that appeared in 2001, reverted to the first (1965 Rotterdam) isolate. Two nucleoside inhibitors brincidofovir and cidofovir have been approved for MPXV treatment. Cidofovir resistance in vaccinia virus is achieved by A314T and A684V mutations. Both A314 and A684 are conserved in MPXV. Therefore, resistance to these drugs in MPXV may arise through similar mechanisms. •L108F in MPXV DNA polymerase emerged in the 2022 outbreak.•L108F can enhance DNA binding affinity, processivity and drug sensitivity of F8L.•Mutation L108F can change the fidelity and sensitivity to nucleoside inhibitors.•G9R mutations that emerged in 2022, are likely to affect interaction of G9R with E4R.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36252459</pmid><doi>10.1016/j.jaut.2022.102928</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6153-8929</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0896-8411
ispartof Journal of autoimmunity, 2022-12, Vol.133, p.102928-102928, Article 102928
issn 0896-8411
1095-9157
1095-9157
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9562781
source MEDLINE; Elsevier ScienceDirect Journals
subjects DNA replication complex
F8L
Family B polymerase
G9R
Monkeypox virus
Mpox (monkeypox)
Mutation
Mutations
Nucleosides
Virus Replication - genetics
title Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A01%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mutations%20in%20the%20monkeypox%20virus%20replication%20complex:%20Potential%20contributing%20factors%20to%20the%202022%20outbreak&rft.jtitle=Journal%20of%20autoimmunity&rft.au=Kannan,%20Saathvik%20R.&rft.date=2022-12-01&rft.volume=133&rft.spage=102928&rft.epage=102928&rft.pages=102928-102928&rft.artnum=102928&rft.issn=0896-8411&rft.eissn=1095-9157&rft_id=info:doi/10.1016/j.jaut.2022.102928&rft_dat=%3Cproquest_pubme%3E2725651883%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2725651883&rft_id=info:pmid/36252459&rft_els_id=S0896841122001366&rfr_iscdi=true